MannKind to Present at Upcoming Investor Conferences

Rhea-AI Summary

MannKind (Nasdaq: MNKD), specializing in inhaled therapeutic products for endocrine and orphan lung diseases, has announced its participation in three major investor conferences during Q1 2025. The company's leadership, including CEO Michael Castagna and CFO Chris Prentiss, will present at:

• Oppenheimer 35th Annual Healthcare Life Sciences Conference (virtual) - February 11, 11:20 a.m. ET
• Leerink Partners 2025 Global Healthcare Conference in Miami - March 11, 8:40 a.m. ET
• Barclays 27th Annual Global Healthcare Conference in Miami - March 12, 1:30 p.m. ET

Live audio webcasts will be accessible through MannKind's investor relations website, with recordings available for approximately 90 days post-conference.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced its participation at three investor conferences during the first quarter of 2025. MannKind’s Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will share updates during the following investor conferences:

Oppenheimer 35^th Annual Healthcare Life Sciences Conference (virtual)
Tuesday, February 11, 11:20 a.m. ET

Leerink Partners 2025 Global Healthcare Conference in Miami
Tuesday, March 11, 8:40 a.m. ET

Barclays 27^th Annual Global Healthcare Conference in Miami
March 12, 1:30 p.m. ET

Links to the live audio webcast of the sessions will be available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations. Recorded versions will also be available on the website for approximately 90 days following the conference.

About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.

We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.

With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.

Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.

FAQ

When is MannKind (MNKD) presenting at the Oppenheimer Healthcare Conference in 2025?

MannKind will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference virtually on Tuesday, February 11, 2025, at 11:20 a.m. ET.

Which investor conferences will MNKD attend in Miami during March 2025?

MNKD will attend two conferences in Miami during March 2025: the Leerink Partners Global Healthcare Conference on March 11 and the Barclays Global Healthcare Conference on March 12.

How long will MNKD's conference presentation recordings be available online?

The recorded versions of MNKD's conference presentations will be available on the company's website for approximately 90 days following each conference.

Where can investors access MNKD's Q1 2025 conference presentations?

Investors can access the live audio webcasts of MNKD's presentations through the company's website at investors.mannkindcorp.com/events-and-presentations.